OraSure Technologies

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OraSure Technologies excels in Q4 2022, eyes strategic partnerships for growth

OraSure Technologies showcased robust financial performance, operational efficiency, and strategic partnerships in Q4 2022.
While facing challenges in margin structure and international mix, the company is focused on core growth and cost-saving initiatives.
Opportunities lie in business unit consolidation, product innovation, and strategic partnerships for future growth and profitability.

OraSure Technologies reports record Q1 revenue, focuses on growth

OraSure Technologies delivered strong Q1 results with record revenue and improved margins, driven by IntelliSwab sales. While facing challenges in product diversification and cost management, the company's focus on efficiency and innovation presents growth opportunities. Strategic partnerships and a solid financial position further support its growth trajectory.

OraSure Technologies reports robust Q2 earnings, eyes growth opportunities ahead

OraSure Technologies delivered strong financial performance in Q2 2023, with revenue growth, operating cash flow, and strategic advancements across key business segments.
While facing challenges in margin improvement and revenue forecasting, the company's focus on cost reductions, operational efficiencies, and growth strategies positions it for long-term success.
By leveraging strengths in core business areas, collaborations, and innovation, OraSure is well-positioned to capitalize on opportunities for accelerated growth and market expansion.

OraSure Technologies excels in Q3 with revenue growth and strategic milestones

OraSure Technologies demonstrated strong financial performance and operational efficiency in Q3 2023, with notable revenue growth and cash flow generation.
While facing challenges in margin moderation and operating expenses, the company's strategic focus on innovation and partnerships presents growth opportunities.
Overall, OraSure's successful milestones, revenue diversification, and cost management efforts position it for continued growth and market leadership.

OraSure Technologies posts strong Q4 results amidst market challenges

OraSure Technologies demonstrated robust financial performance in Q4 2023, driven by revenue diversification and strategic cost-saving initiatives.
While facing challenges in muted core revenue growth for Q1 2024, the company remains confident in its long-term growth prospects.
Strategic partnerships and investments present opportunities for revenue expansion and market penetration in key segments.

OraSure Technologies surpasses Q1 revenue targets, eyes operational breakeven

OraSure Technologies delivered strong financial performance in Q1, exceeding revenue guidance and showcasing core revenue strength.
While facing challenges in business transitions and cost management, the company's strategic focus on efficiency and growth presents opportunities.
With a solid cash position, key partnerships, and a clear roadmap to breakeven in operating cash flow, OraSure is poised for future success.

OraSure Technologies reports robust Q2 results and eyes global expansion

OraSure Technologies delivered strong Q2 financial results with revenue near guidance ranges and operational improvements.
The company faces challenges in cost restructuring and gross margin outlook but sees growth opportunities in new products and partnerships.
International revenue growth, strategic partnerships, and product extensions position OraSure for future success and market expansion.

OraSure Technologies reports stable Q3 performance and eyes growth

OraSure Technologies navigated Q3 with stable financial performance, focusing on core revenue growth and strategic business realignment.
The company's emphasis on innovation, new market entry, and financial strength positions it well for future growth and market expansion.
While challenges like revenue decline and business transitions exist, OraSure Technologies is proactively addressing them to capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.

OraSure (OSUR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for OraSure (OSUR) Stock

Investors applauded the diagnostics company's Q4 update.

Why OraSure Technologies Stock Is Jumping Today

OraSure Technologies, Inc. (NASDAQ:OSUR ) Q4 2022 Earnings Conference Call February 14, 2023 5:00 PM ET Company Participants Scott Gleason - SVP, IR & Corporate Communications Carrie Manner - President, CEO & Director Kenneth McGrath - CFO Conference Call Participants Vijay Kumar - Evercore ISI Elizabeth Speyer - Citigroup Brandon Couillard - Jefferies Jacob Johnson - Stephens Inc. Casey Woodring - JPMorgan Chase & Co. Andrew Cooper - Raymond James & Associates Operator Good day, and thank you pray. Welcome to the OraSure Technologies 2022 Fourth Quarter Earnings Conference Call.

OraSure Technologies, Inc. (OSUR) Q4 2022 Earnings Call Transcript

OraSure (OSUR) delivered earnings and revenue surprises of 2,000% and 26.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

OraSure Technologies (OSUR) Surpasses Q4 Earnings and Revenue Estimates

InteliSwab ® revenue of $88.9 million in Q4, up 12% sequentially; wins two new federal government contracts extending the tail on InteliSwab ® revenue

OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability

BETHLEHEM, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, February 14, 2023.

2022 Fourth Quarter Earnings Conference Call Tuesday, February 14, 2023, 5:00 p.m. ET

Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS Day Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS Day

OraSure Technologies Continues its Dedication to Ending the HIV Epidemic

OraSure Technologies, Inc. Q3 Covid-related revenue continued to dominate top-line growth. Excluding the contribution from Covid-related revenue, the remaining divisional revenue declined 15.4% YoY.

OraSure: Concentration Risk From Covid Revenue, Reaffirm Hold

BETHLEHEM, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Ken McGrath, Chief Financial Officer, will participate in a fireside chat at the Stephens Annual Investment Conference on November 17, 2022 at 9:00 am ET. The conference will be simultaneously webcast over the Internet.

OraSure Technologies to Present at Stephens Annual Investment Conference

OraSure Technologies, Inc. (NASDAQ:OSUR ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Scott Gleason - Senior Vice President of Communications and Investor Relations Carrie Manner - President and Chief Executive Officer Kenneth McGrath - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Inc. Casey Woodring - JPMorgan Chase & Co. Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies' Third Quarter Earnings Conference Call.

OraSure Technologies, Inc. (OSUR) Q3 2022 Earnings Call Transcript

OraSure (OSUR) delivered earnings and revenue surprises of 216.67% and 26.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OraSure Technologies (OSUR) Q3 Earnings and Revenues Top Estimates

InteliSwab® revenue of $79.6 million in Q3, up 85% sequentially; Company continues to expand test production capacity

OraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year

FDA Clearance Received Through Partnership with Grifols to Support Screening for Risk of Alpha1- Antripsyn Deficiency (Alpha-1) in U.S. Adult Population

OraSure Technologies Receives General Clearance for its ORAcollect®•Dx Device for Over-the Counter (OTC) Use from the U.S. Food and Drug Administration (FDA)

BETHLEHEM, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its InteliSwab® COVID-19 Rapid Test is now available in Amazon's online store to customers in the United States. The product will be sold and fulfilled by Amazon and eligible for free Amazon Prime shipping.

InteliSwab® COVID-19 Rapid Test Now Available in Amazon's Online Store

BETHLEHEM, Pa., Nov. 01, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 third quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, November 8, 2022.

2022 Third Quarter Earnings Conference Call Tuesday, November 8, 2022, 5:00 p.m. ET

Arlo Technologies Inc

Wisdomtree Investments

The traditional definition of penny stocks is those companies whose shares trade for $5 or less. It's never easy finding cheap penny stocks to buy amongst this oppressed group because they are often selling at a low share price for a reason.

3 Penny Stocks That Are Too Cheap to Ignore

BETHLEHEM, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Biomedical Advanced Research and Development Authority (BARDA) has issued the Company an $8.6 million contract to develop a 2nd generation Ebola test on the OraQuick® testing platform. The goal is for the 2nd generation test to have improved sensitivity, increased shelf life, new chemistry and more automation when compared to the de novo U.S. Food and Drug Administration (FDA) authorized test. OraSure's OraQuick® Ebola Rapid Antigen test is the only test today with a de novo authorization from the FDA and has been used extensively for Ebola cadaver testing in Africa with results available in 30 minutes.

OraSure Technologies Receives $8.6 Million BARDA Contract to Develop 2nd Generation Ebola Test

The effort promotes HIV testing and awareness in populations disproportionately affected by HIV The effort promotes HIV testing and awareness in populations disproportionately affected by HIV

OraSure Wins Contract to Supply “Together Take Me Home,” HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention

BETHLEHEM, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today a new collaboration between Diversigen, Inc., a subsidiary of OraSure Technologies, and Mars Petcare, which will help researchers better understand pet health. As part of the MARS PETCARE BIOBANK ™ project, Diversigen will sequence microbiome samples from cats and dogs of all breeds and breed makeups in efforts to improve pet care.

OraSure Partners with Mars Petcare in One of the Largest Ever Microbiome Studies to Evaluate Pet Health

OraSure Technologies, Inc. (NASDAQ:OSUR ) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Scott Gleason - Senior Vice President of Investor Relations & Corporate Communications Carrie Manner - President & Chief Executive Officer Kathleen Weber - President of Molecular Solutions Ken McGrath - Chief Financial Officer Lisa Nibauer - President of Diagnostics Conference Call Participants Casey Woodring - JPMorgan Andrew Cooper - Raymond James Operator Welcome to the OraSure Technologies, Incorporated 2022 Second Quarter Earnings Conference Call. My name is Darryl and I will be your operator for today's call.

OraSure Technologies, Inc. (OSUR) CEO Carrie Manner on Q2 2022 Results - Earnings Call Transcript

OraSure (OSUR) delivered earnings and revenue surprises of 100% and 13.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

OraSure Technologies (OSUR) Reports Break-Even Earnings for Q2

InteliSwab ® revenue of $43.1 million in Q2, up 95% sequentially with significant scaling in production

OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year

BETHLEHEM, Pa., Aug. 02, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 second quarter financial results and certain business developments for 5:00 p.m. ET (2:00 p.m. PT) on Tuesday, August 9, 2022.

OraSure Technologies to Hold 2022 Second Quarter Earnings Conference Call Tuesday, August 9, 2022, 5:00 p.m. ET

Race to End Hep C initiative demonstrates the ability of easy-to-administer, low-cost testing solutions to identify patients and direct them to appropriate care Race to End Hep C initiative demonstrates the ability of easy-to-administer, low-cost testing solutions to identify patients and direct them to appropriate care

OraSure's Ongoing Commitment to End the Hepatitis C Epidemic Heats Up at the Racetrack

BETHLEHEM, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its OMNIgene®•GUT DNA and RNA product (OMR-205) is now available to gut microbiome researchers. The product allows for self-collection, stabilization, storage and transportation of both microbial DNA and RNA at ambient temperature for gut microbiome profiling. It is made by OraSure's subsidiary DNA Genotek.

News for OraSure Technologies Stock (OSUR)